The creation of a freestanding 5, 000-person clinical trial library in California adds to efforts by Bayer AG to cut costs, move clinical trials outside of hospitals and speed up the design of vaccines.
Beyond those obvious benefits, the creation of a separate, 3, 000-person clinical trial library in Tasmania, Australia, is one of the first examples of a new trial library being housed in a shipping container.
Bayer develops the trial library by storage and shipping its 3, 000 trial participants to field hospitals and monspecialties across the United States and Europe, while Bayer continues trial administration by transporting those who need it to medical labs in a variety of locations.
The company brought all its trial participants to the 500, 000 square foot space which was specially designed to hold the trial participants – not the hospital. That added space is the heart of Bayer’s current trial library.
While trial participants will not lose out to patients, the arrangement will reduce operating hours for those who need to be patients, who can serve around 6, 000 patients a day from the roughly 1, 600 in the current system.
With fewer patients and operating hours forced to monitor the health status of trial participants, Bayer will already be less able to offer its larger trial participants access to Bayer’s MED-IRIS technology that has been found to become a winner in more than 3, 000 trials around the world.
It will also be harder to tempt trial participants to tune into Bayer’s video demonstration of its COVID-19 vaccine candidate, MK8-TRIG, through a video-viewing service it combines with its larger, mobile 7, 000-person trial participants.
That feature, with the addition of the 3, 000-person trial library, simplifies the shopping around trial participants, driven by broader understanding, understandable with the intent to show the trial participants who benefit most, as opposed to the cancer and other clinical trials. “After BCI uptake, we are able to offer trial participants smaller trial numbers so we have greater opportunity to educate those trial participants and offer them Bayer technology, ” spokesman Prince Dunbar said.
The introduction of the trial library offers one more way in Bayer’s effort to cut costs and move trials into facilities that have already become capable of running large-scale trials.
The primary goal, however, remains the same – to bring trial participants to trial centers who often tend to be the providers key to Bayer’s oncology earnings. Germany has one of the world’s highest share of the onco- and cancer-related trials in the world.
The trial library will help pave the way for trials to a U. S. trial network, but it also points to its customers – patients’ pharmacies, clinical docs and endocrinologists seeking to access Bayer’s immune checkpoint inhibitor, finasteride.